Foghorn Therapeutics ends Eli Lilly cancer partnership and cuts 40 percent of staff

Foghorn Therapeutics Inc., a clinical-stage biotechnology company headquartered in Watertown, Massachusetts, has ended its oncology collaboration with Eli Lilly and Company and will cut roughly 40 percent of its workforce after its lead partnered cancer candidate failed to deliver enough benefit in an early-stage human trial. The Nasdaq-listed company, which trades under the ticker FHTX, said the decision came after a review of clinical data from the Phase 1 dose escalation trial of FHD-909, also known as LY4050784.

The drug was designed as a first-in-class, orally available small molecule that selectively inhibits the ATPase activity of SMARCA2, also called BRM, over its closely related paralog SMARCA4, also called BRG1. Those two proteins are the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system. FHD-909 was intended to treat certain lung and other solid tumours with changes in the SMARCA4 gene.

The scientific bet rested on a concept known as synthetic lethality. In tumours that have already lost SMARCA4, blocking SMARCA2 is supposed to push cancer cells past a point where they can survive and divide. That idea has attracted substantial interest across oncology research, but it has also proven difficult to convert into measurable patient benefit, and Foghorn is now the latest company to run into that wall.

Reuters reported on October 1, 2026 that Foghorn has discontinued development of the Lilly-partnered drug, will not extend the 2021 partnership, and is cutting about 40 percent of its workforce. Shares of the biotech were down more than 48 percent in premarket trading. The job cuts are expected to be completed in the fourth quarter.

Key Facts

Foghorn and Lilly decided not to advance FHD-909 into the clinical development expansion phase, and they will also not advance a separate selective SMARCA2 degrader program. BioSpace reported on October 1, 2026 that the companies do not anticipate further collaboration activities, leaving the biotech to reprioritize its wholly owned pipeline. GlobeNewswire reported on October 1, 2026 that the company is shifting resources toward programs with the greatest potential to address significant patient needs and create long-term value.

The original 2021 deal was struck with Lilly subsidiary Loxo Oncology, which paid $300 million in cash upfront and made an $80 million equity investment in Foghorn common shares at $20 per share. The arrangement covered co-development and co-commercialization of products from Foghorn's selective BRM oncology program and carried a total headline value of up to $1.6 billion.

The workforce reduction will leave Foghorn with about 65 full-time employees, down from 106 at the end of 2025. Reuters reported on October 1, 2026 that the company expects to record about $2.3 million in charges related to the layoffs. Management said the cost reductions, combined with pipeline prioritization, should extend its cash runway into the second half of 2029.

As of June 30, 2026, the company reported an accumulated deficit of $659.5 million and cash, cash equivalents and marketable securities of $167.6 million. Dow Jones Newswires reported on October 1, 2026 that the stock was down 44 percent to $2.00 in premarket trading, while BioSpace noted the shares opened at $2.08 after losing more than 40 percent of their value.

Chief executive officer Adrian Gottschalk said the company and Lilly developed a drug in FHD-909 that selectively hits the SMARCA2 target with a favorable safety profile at exposures that exceeded preclinical targets. He said the biology of the SMARCA2 and SMARCA4 synthetic lethality relationship has not translated into the level of efficacy required to further advance the program.

Analysis

The bigger picture here is that a clean safety profile and on-target engagement are no longer enough to carry an oncology program forward. Foghorn and Lilly built a molecule that did what it was designed to do at the molecular level, hitting SMARCA2 selectively at exposures above preclinical thresholds, and it still failed the efficacy bar. That is a scientific disappointment rather than an execution failure, and it raises hard questions about how much of the synthetic lethality thesis can be rescued by better chemistry or better patient selection.

The commercial math was already unforgiving. A collaboration valued at up to $1.6 billion, anchored by $300 million in cash upfront and an $80 million equity investment at $20 per share, has now produced no expansion-phase asset. Foghorn's shares, which had already been trading at a small fraction of that $20 equity price, fell more than 48 percent in premarket trading, and one report put the decline near 49 percent to $1.84.

The roughly 40 percent workforce cut, from 106 employees at the end of 2025 to about 65, is a survival move rather than a strategic pivot in the ordinary sense. Foghorn is trading near-term optionality for time, accepting about $2.3 million in restructuring charges to push its cash runway into the second half of 2029. With an accumulated deficit of $659.5 million and $167.6 million in cash and marketable securities as of June 30, 2026, that runway extension is arguably the most valuable thing the company bought this quarter.

What this really means is that Foghorn is now a different company than the one Lilly partnered with in 2021. The remaining value sits in wholly owned assets and platforms rather than in a large pharma alliance, and the burden of proof has shifted entirely onto data the company will have to generate on its own balance sheet. Partnerships of this size are frequently described as validation, but validation expires the moment the data turns.

Why It Matters

For patients with SMARCA4-altered lung and other solid tumours, the near-term pipeline just got thinner. A first-in-class oral agent aimed at a genetically defined dependency was one of the few shots on goal in this niche, and its withdrawal removes an option that had already reached human testing. Any successor will have to clear the same efficacy bar, and that bar has now been set by a molecule that hit its intended target safely.

For the wider biotech sector, the news is a reminder of how quickly a large partnership can evaporate when Phase 1 dose escalation data disappoints. The 2021 structure, with $300 million upfront and an $80 million equity investment, was strong validation at the time. Ending the alliance less than five years later shows that upfront payments buy optionality, not insurance, and that an equity stake taken at $20 per share can look very different when the shares change hands near $2.

For Eli Lilly and Loxo Oncology, the retreat trims an early-stage oncology bet without disrupting a much larger portfolio. Still, walking away from both FHD-909 and the separate selective SMARCA2 degrader program closes off an entire branch of the collaboration rather than a single molecule, which narrows the strategic relationship to essentially nothing.

Next Up

Foghorn said it will concentrate resources on its proprietary portfolio, including a selective EP300 degrader program, a selective CBP degrader program, a novel oral immunology and inflammation program, and an induced proximity platform. Those assets, along with the company's Gene Traffic Control discovery platform, now carry the story for a company that once leaned on a pharma partner to fund its most advanced oncology work.

Investors will be watching for updated cash guidance, confirmation that the layoffs are largely complete this quarter, and any early clinical data from the prioritized programs, since the runway into the second half of 2029 depends on those programs producing results before the money runs out.